Page 82 - Memora anual Fundación CIEN 2017

this project will allow us to understand the genetics Additionally, in the context of the DEGESCO consor-
of AD thus improving our knowledge of the underl- tium, collaboration has begun with the GR@ACE
ying pathophysiological processes in the disease; project, led by the ACE Foundation, which will be
since the genetic factors seem to represent up to carried out in three years, and whose objective is the
80% of the attributable risk in AD. In parallel, the application of high resolution genomic technologies
EADB will collect DNA samples from the largest Euro- for the identification of a new generation of genes
pean longitudinal cohort of cases of mild cognitive that contribute data in the design of new treatments
impairment, with the aim of identifying genetic mar- to deal with Alzheimer's disease.
kers that modulate the rate of disease progression
and cognitive decline. From a translational pers- In relation to the study of biomarkers and the colla-
pective, the identification of genetic factors in the borative context with the company Biocross SL and
pathways that modulate AD risk and increase the with various Spanish hospitals, we continue with the
rate of disease progression/cognitive decline will be plasma metabolomic studies of people with Alzhei-
critical for the development and testing of thera- mer's disease, mild cognitive impairment or without
peutic approaches. cognitive dysfunction. In addition, we also continue

Illustration of the concept of endophenotypes for defining homogenous
populations based on certain genetic variants and biomarkers
in Alzheimer's disease. Modified from During et al. 2011

The construct of Diagnostic or
endophenotype predictive marker

Epigenetics

AD -related

Genes Exploration of Abnormalities Prediction AD

risk factors in cognitively of the disease dementia

normal subjects

Environment

CIEN Foundation Annual Report 2017 / 82